Journal
CLINICA CHIMICA ACTA
Volume 491, Issue -, Pages 1-7Publisher
ELSEVIER
DOI: 10.1016/j.cca.2019.01.003
Keywords
Cancer; Small Leucine Rich Proteoglycans (SLRPs); Decorin; Biglycan; Lumican
Categories
Ask authors/readers for more resources
The extracellular matrix (ECM) prevents invasion of tumour cells and possesses an intrinsic mechanism to down regulate signalling processes that promote cancer proliferation. Small Leucine Rich Proteoglycans (SLRPs) are ubiquitous ECM components involved in matrix structural organization and as such can potentially regulate cancer cell multiplication, angiogenesis and migration. Decorin, a class I SLRP that modulates collagen fibrillogenesis, also functions as a natural pan-tyrosine kinase inhibitor to reduce tumour growth. In fact, decreased decorin expression has been associated with tumour aggressiveness and lower survival. In contrast, biglycan, another class I SLRP, was highly expressed in cancer and was associated with metastatic activity and lower survival. Tissue expression of lumican, a class II SLRP, was associated with clinical outcome and appears tumour specific. Recently, decorin, biglycan and lumican were found to be potential biomarkers in bladder cancer. This review updates our current understanding on the molecular interplay and significance of decorin, biglycan and lumican expression in cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available